Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00696449 · ClinicalTrials.gov registry record · Phase 4
Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris
A Phase 4 study, sponsored by Wake Forest University.
- Completed
- Registry status
- Phase 4
- Development phase
- 61
- Enrollment target
NCT00696449 is a Phase 4 study that has completed, run by Wake Forest University. The registered enrollment target is 61 participants.
The verdict
NCT00696449, a Phase 4 study, has completed, sponsored by Wake Forest University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 61 participants
- Enrollment target
Study Summary
The primary objective of this study is to investigate potential differences between four treatment intervention groups in the adherence to treatment with Differin® Gel, 0.1%. Differin is approved by the Food and Drug Administration (FDA) to treat acne.
Interventions
- BEHAVIORAL Standard of care
- DRUG Adapalene
- BEHAVIORAL frequent visits
- BEHAVIORAL electronic reminder
- BEHAVIORAL Parent reminder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00696449
The ClinicalTrials.gov registry entry for NCT00696449 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Standard of care is the first listed.
NCT00696449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00696449 about?
NCT00696449 is a clinical study titled "Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris". The primary objective of this study is to investigate potential differences between four treatment intervention groups in the adherence to treatment with Differin® Gel, 0.1%. Differin is approved by the Food and Drug Administration (FDA) to treat acne.
What is the current status of trial NCT00696449?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 61 participants. The study started on 2006-06. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00696449?
The interventions under investigation include: Standard of care (BEHAVIORAL), Adapalene (DRUG), frequent visits (BEHAVIORAL), electronic reminder (BEHAVIORAL), Parent reminder (BEHAVIORAL).
Who is sponsoring clinical trial NCT00696449?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.